SARS-CoV-2

Akshit Sharma1, Shweata Maurya1, Shivank Kumar1

  • 1Laboratory for Computational Biology & Biomolecular Design, School of Biochemical Engineering, Indian Institute of Technology (BHU), Varanasi 221005, Uttar Pradesh, India.

Biophysical journal
|May 21, 2025
PubMed
概括

这项研究开发了一种综合框架,以识别SARS-CoV-2尖端蛋白突变,从而产生对关键单克隆抗体治疗方法索特罗维马布的耐药性. 这些发现与临床数据一致,有助于理解耐药性和设计新的抗体疗法.